Cardiovascular Health

Cardiovascular health protocols using peptides for cardiac function, vascular integrity, and atherosclerotic risk. Cardiac peptide therapy is not science fiction — TB4 has completed Phase 2 in acute MI, and SS-31 sits in active trials for heart failure. Mitochondria-derived peptides like SS-31 and MOTS-c are rewriting the rules of cellular energy for vascular and cardiac tissue. The age equation matters here: the same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50.